Cancer Immunotherapy

NY-ESO-1 Expression Could Be Exploited for Immunotherapy

Published in Cancer Weekly, April 26th, 1999

NY-ESO-1 gene expression may be a viable lung cancer immunotherapy target.

L. Lee and colleagues from the U.S. National Cancer Institute, Bethesda, Maryland, evaluated the frequency of NY-ESO-1 expression in cultured lung cancer cells to determine if this cancer-testis antigen could be presented for recognition by an HLA-restricted cytolytic T-cell clone specific for NY-ESO-1 ("NY-ESO-1 May Be a Potential Target for Lung Cancer Immunotherapy," Cancer Journal from Scientific American, January-February 1999;5(1):20-25).

"Reverse transcriptase and polymerase chain reaction amplification techniques were utilized to screen a panel of lung and esophageal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry